Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. shareholders approved an amendment to the 2019 Equity Incentive Plan, increasing the number of ordinary shares authorized for issuance by 6,800,000. Additionally, shareholders elected eight directors to the Board, ratified PricewaterhouseCoopers LLP as the company's auditor, and approved the non-binding advisory vote on executive compensation. All proposals presented at the Annual Meeting on June 10, 2026, were passed.

Milestone Pharmaceuticals Inc. announced that its management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET, with a replay accessible for approximately 90 days on the company's website. Milestone Pharmaceuticals is focused on developing innovative cardiovascular medicines, with its lead product, CARDAMYST (etripamil) nasal spray, being FDA-approved for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT).

Milestone Pharmaceuticals reported a net loss of $26.1 million for Q1 2026, compared to a $20.8 million loss in the prior year, with product revenues of $0.2 million from the recent CARDAMYST launch. The company secured Express Scripts national formulary coverage for CARDAMYST, which is gaining traction with approximately 600 scripts filled and 400 unique prescribers. Milestone also initiated a Phase 3 registrational trial for etripamil in AFib-RVR and maintains a strong balance sheet of $184.2 million, providing a runway into H2 2027.

Milestone Pharmaceuticals Inc. reported its first quarter 2026 financial results, highlighting positive traction for its CARDAMYST™ (etripamil) nasal spray launch for PSVT. The company secured national formulary coverage with Express Scripts, making CARDAMYST accessible to over 25% of commercially insured lives. Additionally, Milestone initiated a Phase 3 registration trial for etripamil in Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR), with patient enrollment expected in the second half of 2026. The company maintains a strong balance sheet with $184.2 million in cash, providing a runway into H2 2027.

Milestone Pharmaceuticals reported a net loss of $26.1 million for Q1 2026, an increase from $20.8 million in Q1 2025, though net loss per share improved to $(0.20). This quarter marks the first product revenue from CARDAMYST™ (etripamil) nasal spray, totaling $0.2 million, following its FDA approval in December 2025. The company secured $75.0 million from a royalty financing arrangement, contributing to a significant increase in total assets and liabilities, and states it has sufficient liquidity for the next 12 months.

Milestone Pharmaceuticals Inc. announced it will report its financial results for the first quarter ended March 31, 2026, and provide a business update before market open on Wednesday, May 13, 2026. This announcement will be followed by a conference call and webcast for investors at 8:30am ET. Details for accessing the conference call and webcast have been provided.

Milestone Pharmaceuticals Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on June 10, 2026. Shareholders will vote on the election of eight directors, ratification of PwC as auditor, approval to increase shares for the 2019 Equity Incentive Plan by 6,800,000, and a non-binding advisory vote on executive compensation. The record date for voting is April 15, 2026, with 119,637,391 common shares outstanding.

Milestone Pharmaceuticals Inc. announced the initiation of RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry for its recently FDA-approved CARDAMYST™ (etripamil) nasal spray. The registry aims to generate real-world evidence on CARDAMYST's use in adults with paroxysmal supraventricular tachycardia (PSVT), expanding beyond controlled clinical trials. Led by the Duke Clinical Research Institute, the study is expected to enroll approximately 450 adult patients across 20 electrophysiology and cardiology sites, with enrollment commencing by the end of 2026. This initiative is crucial for understanding CARDAMYST's utilization in routine care, capturing patient-reported outcomes, and informing healthcare providers about its value in acute PSVT management.